Improving the pharmacokinetic performance of oral and topical CBD applications with VESIsorb® technology-based product formulations – white paper

The superior pharmacokinetic (PK) performance of VESIsorb® formulated natural products, such as coenzyme Q10, is widely recognized in the global marketplace. The emergence of cannabinoids, from both hemp extract and marijuana, has captured the imagination of consumers and health care professionals alike in recent years. Unfortunately, it is clear in the scientific community that these cannabinoids, including CBD, are very poorly absorbed. CBD shows limited oral bioavailability due to its poor aqueous solubility and extensive first-pass metabolism. To overcome these limitations, a novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb formulation technology was developed. A study was conducted with the objective to evaluate the PK profile of the VESIsorb CBD formulation in a randomized, double-blind, cross-over design under fasted conditions. The study demonstrated that the VESIsorb delivery system provides the formulation solution needed to ensure the dramatically improved absorption and bioavailability of CBD that’s necessary to provide the therapeutic health benefits – safely and effectively – that so many are seeking from CBD.